Segment Information - Schedule of Company Revenue and Adjusted EBITDA by Segment (Details) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022
Segment Revenue
Recognized revenue			$ 219,638,000	$ 299,489,000	$ 271,893,000
Segment Adjusted EBITDA
Total Adjusted EBITDA			(175,796,000)	(161,301,000)	(150,740,000)
Adjustments
Net loss			(666,704,000)	(311,656,000)	(217,490,000)
Interest income, net			(14,331,000)	(9,676,000)	(277,000)
Other (income) expense, net			(506,000)	93,000	83,000
Changes in fair value of warrant liabilities			0	0	(32,989,000)
Provision for (benefit from) income taxes			73,000	(2,772,000)	(3,480,000)
Depreciation and amortization			18,033,000	20,239,000	18,899,000
Amortization of acquired intangible assets			11,448,000	16,486,000	7,269,000
Impairment of acquired intangible assets			0	9,968,000	0
Stock-based compensation expense			120,209,000	116,017,000	57,933,000
Acquisition-related costs			0	0	9,362,000
Litigation settlement, net			98,000	0	9,950,000
Loss on disposition and transaction-related costs			2,375,000	0	0
Goodwill impairment	$ 152,900,000	$ 198,800,000	351,744,000	0	0
Cybersecurity incident expenses, net of probable insurance recoveries			1,765,000	0	0
Total Adjusted EBITDA			(175,796,000)	(161,301,000)	(150,740,000)
Corporate, Non-Segment
Segment Adjusted EBITDA
Total Adjusted EBITDA			(48,002,000)	(54,801,000)	(43,684,000)
Consumer and Research Services
Segment Revenue
Recognized revenue			219,638,000	299,489,000	271,893,000
Consumer and Research Services | Operating Segments
Segment Adjusted EBITDA
Total Adjusted EBITDA			(36,769,000)	(17,997,000)	(30,112,000)
Therapeutics
Segment Revenue
Recognized revenue			0	0	0
Therapeutics | Operating Segments
Segment Adjusted EBITDA
Total Adjusted EBITDA			$ (91,025,000)	$ (88,503,000)	$ (76,944,000)